A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma

Histopathology

Volumn 65, Issue 5, 2014, Pages 726-728

  Martinez Rodriguez, Miguel ^a,b   Thompson, Alec K ^b   Monteagudo, Carlos ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b TELEMARK HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN;

DISEASE COURSE; FEMALE; HUMAN; MALE; MELANOMA; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS;

ANTIGENS, CD20; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PROGNOSIS;

EID: 84911166897     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12437     Document Type: Letter

References (11)

1. Linnebacher M. Tumor-infiltrating B cells come into vogue. World J. Gastroenterol. 2013; 19; 8-11.
2. Ladányi A, Kiss J, Mohos A et al. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol. Immunother. 2011; 60; 1729-1738.
3. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969; 29; 705-727.
4. Day CL Jr, Sober AJ, Kopf AW et al. A prognosis model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann. Surg. 1981; 193; 436-440.
5. Clark WH Jr, Elder DE, Guerry D 4th et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 1989; 81; 1893-1904.
6. Clemente C, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77; 1303-1310.
7. Azimi F, Scolyer RA, Rumcheva P et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J. Clin. Oncol. 2012; 30; 2678-2683.
8. Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C. B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2013; 2; e25443.
9. Carpenter EL, Mick R, Rech AJ et al. Collapse of the CD27 + B cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin. Cancer Res. 2009; 15; 4277-4287.
10. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Prac. Oncol. 2005; 2; 416-422.
11. Schramm SJ, Mann GJ. Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol. Cancer Ther. 2011; 10; 1520-1528.